Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group

Abstract

DC resulted in a more favorable overall response and survival rate than VC. Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC. These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.

Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer

“…In this study, docetaxel and cisplatin (a combination noted for its activity relative to other platinum-based doublets as first-line therapy in advanced NSCLC (Fossella et al, 2003)) resulted in no PD (i.e. achieved PR or NC) in 88% of patients.…”

What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis

“…Several trials in the past compared regimens containing cisplatin vs carboplatin with conflicting results [26][27][28][29][30][31][32][33]. In 2007, an individual patient data meta-analysis performed by Ardizzoni et al [34], including 9 of these trials and comparing cisplatin VS carboplatin-based chemotherapy in 2968 NSCLC patients, showed a significant improvement of ORR in favour of cisplatin arm (30% VS 24%; OR: 1.37, P < 0.001), while no significant differences between two arms were observed in survival rate.…”

Treatment with a Small Synthetic Compound, KMU-193, induces Apoptosis in A549 Human Lung Carcinoma Cells through p53 Up-Regulation

“…The disease control has been achieved with classical doublet chemotherapy in advanced or metastatic non-small cell lung cancer. However it is usually restricted to only a few months (Scagliotti et al, 2002;Schiller et al, 2002;Fossella et al, 2003;Sledge, 2005;Binder and Hegenbarth, 2013). Though, recently, therapies directed against the epidermal growth factor receptor have been incorporated into daily clinical practice, the current 5-year survival rate of lung cancer is approximately 20% (Xu et al, 2011).…”